TrimTabs-国际自由现金流优质主动型ETF TTAI 深 沪
等待开盘 04-03 09:30:00 美东时间
29.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 29.99
- 总市值 5998.00万
- 52周最高 30.3535
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 26.591
- 委 比 0.00%
- 总股本 200.00万
- 历史最高 32.324
- 量 比 0
- 振 幅 0.00%
- 历史最低 10.621
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Globalstar, Exxon Mobil, Cyclerion Therapeutics, Eli Lilly And Intel: Why These 5 Stocks Are On Investors' Radars Today
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.
04-02 10:33
What's Going On With Structure Therapeutics Stock On Wednesday?
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
04-02 02:07
Why Is Eli Lilly Stock Gaining Today?
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
04-02 01:08
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly's orforglipron
Positive phase 2 results from Jiangsu Hengrui Pharmaceuticals (JNGHF)(JHPCY) and privately held Kailera Therapeutics for their daily oral GLP-1/GIP receptor dual agonist peptide ribupatide for obesity...
02-11 04:17
BRIEF-Eli Lilly Says Orforglipron Achieves Primary And Secondary Endpoints In ATTAIN-MAINTAIN Study
Dec 18 (Reuters) - Eli Lilly and Co LLY.N: ELI LILLY: SUBMITTED ORFORGLIPRON TO THE U.S. FDA FOR TREATMENT OF OBESITY ELI LILLY: ORFORGLIPRON ACHIEVES PRIMARY AND SECONDARY ENDPOINTS IN ATTAIN-MAINTAI...
2025-12-18 19:45
BRIEF-Eli Lilly Announces Positive Topline Results From Phase 3 ATTAIN-2 Trial,Evaluating Oral GLP-1 Receptor Agonist
Aug 26 (Reuters) - Eli Lilly and Co LLY.N: ELI LILLY: POSITIVE TOPLINE RESULTS FROM PHASE 3 ATTAIN-2 TRIAL, EVALUATING ORAL GLP-1 RECEPTOR AGONIST, ORFORGLIPRON ELI LILLY: IN TRIAL, ALL THREE DOSES...
2025-08-26 18:45
BRIEF-Lilly's Oral Glp-1, Orforglipron, Delivers Weight Loss Of Up To An Average Of 27.3 Lbs In First Of Two Pivotal Phase 3 Trials In Adults With Obesity
Aug 7 (Reuters) - Eli Lilly and Co LLY.N: LILLY'S ORAL GLP-1, ORFORGLIPRON, DELIVERS WEIGHT LOSS OF UP TO AN AVERAGE OF 27.3 LBS IN FIRST OF TWO PIVOTAL PHASE 3 TRIALS IN ADULTS WITH OBESITY ELI LILLY...
2025-08-07 20:25
Eli Lilly Announces Positive Phase 3 Trial Results for Orforglipron, Demonstrating Significant Weight Loss in Adults with Obesity
Eli Lilly and Company has announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating the investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, in 3,1...
2025-08-07 18:25
BRIEF-Sdre Secures $150 Million Financing To Expand Attainable Housing Opportunities In San Diego
SDRE SECURES $150 MILLION FINANCING TO EXPAND ATTAINABLE HOUSING OPPORTUNITIES IN SAN DIEGO Source text: ID:nPn5pCcHNa Further company coverage: [ ]
2025-07-30 05:26
